Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 160,900 shares, a growth of 32.2% from the April 15th total of 121,700 shares. Based on an average trading volume of 92,000 shares, the days-to-cover ratio is […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 121,700 shares, a decrease of 35.4% from the March 31st total of 188,300 shares. Approximately 1.1% of the shares of the stock are short […]
Needham & Company LLC reiterated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Get Rating) in a research report released on Friday morning, Benzinga reports. The firm currently has a $2.60 target price on the stock. Lucid Diagnostics Stock Down 1.9 % LUCD opened at $1.53 on Friday. The stock has a market […]
Needham & Company LLC reissued their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Get Rating) in a report published on Friday, Benzinga reports. The firm currently has a $2.60 price target on the stock. Lucid Diagnostics Stock Down 1.9 % Shares of NASDAQ:LUCD opened at $1.53 on Friday. The firm has a market […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 188,300 shares, an increase of 41.0% from the March 15th total of 133,500 shares. Based on an average daily volume of 108,600 shares, the short-interest ratio is presently 1.7 days. […]